Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials-Reference-Cited by-同舟云学术

Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials

Published:2023-08-07 Issue:10 Volume:64 Page:1643-1654
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gong Inna Y.¹,Aminilari Mahmood²,Landego Ivan³,Hueniken Katrina²,Zhou Qianghua⁴^ORCID,Kuruvilla John¹³^ORCID,Hodgson David C.¹²^ORCID

Affiliation:

1. Department of Radiation Medicine, University of Toronto, Toronto, Ontario, Canada

2. Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

3. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2234528

Reference58 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

4. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

5. Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial;Nature Medicine;2023-12-10